Meeting Abstract
Autorenliste: Khanna, Dinesh; Denton, Christopher; Spotswood, Helen; Jahreis, Angelika; van Laar, Jacob M.; Burke, Laura; Lin, Celia J. F.; Pope, Janet E.; Allanore, Yannick; Mueller-Ladner, Ulf; Siegel, Jeffrey; Furst, Daniel E.
Jahr der Veröffentlichung: 2016
Zeitschrift: Arthritis & Rheumatology
Bandnummer: 68
ISSN: 2326-5191
eISSN: 2326-5205
Konferenz: Annual Meeting of the American-College-of-Rheumatology/Association-of-Rheumatology-Health-Professionals (ACR/ARHP)
Verlag: Wiley
Zitierstile
Harvard-Zitierstil: Khanna, D., Denton, C., Spotswood, H., Jahreis, A., van Laar, J., Burke, L., et al. (2016) Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial, Arthritis & Rheumatology, 68
APA-Zitierstil: Khanna, D., Denton, C., Spotswood, H., Jahreis, A., van Laar, J., Burke, L., Lin, C., Pope, J., Allanore, Y., Mueller-Ladner, U., Siegel, J., & Furst, D. (2016). Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial. Arthritis & Rheumatology. 68.
